354,555 Shares in Danaher Corporation (NYSE:DHR) Purchased by Jennison Associates LLC

Jennison Associates LLC acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 354,555 shares of the conglomerate's stock, valued at approximately $72,684,000.

A number of other institutional investors also recently modified their holdings of the company. Burling Wealth Partners LLC lifted its position in shares of Danaher by 1.9% during the 1st quarter. Burling Wealth Partners LLC now owns 25,849 shares of the conglomerate's stock valued at $5,299,000 after acquiring an additional 472 shares during the period. Hardy Reed LLC lifted its position in shares of Danaher by 38.3% during the 1st quarter. Hardy Reed LLC now owns 7,563 shares of the conglomerate's stock valued at $1,550,000 after acquiring an additional 2,093 shares during the period. Commerzbank Aktiengesellschaft FI lifted its position in shares of Danaher by 0.8% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 7,905 shares of the conglomerate's stock valued at $1,621,000 after acquiring an additional 65 shares during the period. Kingsview Wealth Management LLC lifted its position in shares of Danaher by 410.7% during the 1st quarter. Kingsview Wealth Management LLC now owns 208,359 shares of the conglomerate's stock valued at $42,714,000 after acquiring an additional 167,564 shares during the period. Finally, Montis Financial LLC lifted its position in shares of Danaher by 14.5% during the 1st quarter. Montis Financial LLC now owns 1,756 shares of the conglomerate's stock valued at $360,000 after acquiring an additional 223 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 2.5%

Shares of DHR stock traded down $4.81 during mid-day trading on Friday, reaching $189.98. 4,239,169 shares of the company's stock traded hands, compared to its average volume of 3,523,488. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a market cap of $135.96 billion, a P/E ratio of 36.89, a P/E/G ratio of 2.67 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The company's 50-day moving average price is $196.13 and its 200-day moving average price is $205.03.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher's dividend payout ratio is 24.85%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Barclays reiterated an "overweight" rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating on shares of Danaher in a report on Monday, April 7th. Finally, UBS Group reduced their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $248.48.

Insider Activity at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.